electroCore, Inc.
NASDAQ:ECOR
electroCore, Inc.
Income from Continuing Operations
electroCore, Inc.
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
electroCore, Inc.
NASDAQ:ECOR
|
Income from Continuing Operations
-$11.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Income from Continuing Operations
$1.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
4%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Income from Continuing Operations
$1.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Income from Continuing Operations
$3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
19%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Income from Continuing Operations
$13.4B
|
CAGR 3-Years
24%
|
CAGR 5-Years
30%
|
CAGR 10-Years
23%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Income from Continuing Operations
$2.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
|
electroCore, Inc.
Glance View
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
See Also
What is electroCore, Inc.'s Income from Continuing Operations?
Income from Continuing Operations
-11.9m
USD
Based on the financial report for Dec 31, 2024, electroCore, Inc.'s Income from Continuing Operations amounts to -11.9m USD.
What is electroCore, Inc.'s Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
23%
Over the last year, the Income from Continuing Operations growth was 37%. The average annual Income from Continuing Operations growth rates for electroCore, Inc. have been 12% over the past three years , 23% over the past five years .
You don't have any saved screeners yet